Summary | |
---|---|
Symbol | PGR |
Name | progesterone receptor |
Aliases | NR3C3; nuclear receptor subfamily 3 group C member 3 |
Chromosomal Location | 11q22-q23 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway |
Subcellular Location | Nucleus. Cytoplasm. Note=Nucleoplasmic shuttling is both hormone- and cell cycle-dependent. On hormone stimulation, retained in the cytoplasm in the G(1) and G(2)/M phases.; SUBCELLULAR LOCATION: Isoform A: Nucleus. Cytoplasm. Note=Mainly nuclear.; SUBCELLULAR LOCATION: Isoform 4: Mitochondrion outer membrane |
Domain |
PF00104 Ligand-binding domain of nuclear hormone receptor PF02161 Progesterone receptor PF00105 Zinc finger |
Function |
The steroid hormones and their receptors are involved in the regulation of eukaryotic gene expression and affect cellular proliferation and differentiation in target tissues. Depending on the isoform, progesterone receptor functions as transcriptional activator or repressor. ; FUNCTION: Isoform A: Ligand-dependent transdominant repressor of steroid hormone receptor transcriptional activity including repression of its isoform B, MR and ER. Transrepressional activity may involve recruitment of corepressor NCOR2. ; FUNCTION: Isoform B: Transcriptional activator of several progesteron-dependent promoters in a variety of cell types. Involved in activation of SRC-dependent MAPK signaling on hormone stimulation. ; FUNCTION: Isoform 4: Increases mitochondrial membrane potential and cellular respiration upon stimulation by progesterone. |
Biological Process |
GO:0006352 DNA-templated transcription, initiation GO:0006367 transcription initiation from RNA polymerase II promoter GO:0009755 hormone-mediated signaling pathway GO:0043401 steroid hormone mediated signaling pathway GO:0048545 response to steroid hormone GO:0071383 cellular response to steroid hormone stimulus GO:0071396 cellular response to lipid GO:0071407 cellular response to organic cyclic compound |
Molecular Function |
GO:0000978 RNA polymerase II core promoter proximal region sequence-specific DNA binding GO:0000982 transcription factor activity, RNA polymerase II core promoter proximal region sequence-specific binding GO:0000987 core promoter proximal region sequence-specific DNA binding GO:0001077 transcriptional activator activity, RNA polymerase II core promoter proximal region sequence-specific binding GO:0001159 core promoter proximal region DNA binding GO:0001228 transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding GO:0003707 steroid hormone receptor activity GO:0005496 steroid binding GO:0051117 ATPase binding |
Cellular Component |
GO:0005741 mitochondrial outer membrane GO:0019867 outer membrane GO:0031968 organelle outer membrane |
KEGG |
hsa04114 Oocyte meiosis hsa04914 Progesterone-mediated oocyte maturation |
Reactome |
R-HSA-74160: Gene Expression R-HSA-212436: Generic Transcription Pathway R-HSA-383280: Nuclear Receptor transcription pathway R-HSA-1251985: Nuclear signaling by ERBB4 R-HSA-162582: Signal Transduction R-HSA-1236394: Signaling by ERBB4 |
Summary | |
---|---|
Symbol | PGR |
Name | progesterone receptor |
Aliases | NR3C3; nuclear receptor subfamily 3 group C member 3 |
Chromosomal Location | 11q22-q23 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Literatures that report relations between PGR and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells. |
Literatures describing the relation between PGR and anti-tumor immunity in human cancer.
|
Summary | |
---|---|
Symbol | PGR |
Name | progesterone receptor |
Aliases | NR3C3; nuclear receptor subfamily 3 group C member 3 |
Chromosomal Location | 11q22-q23 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets. |
> High-throughput Screening
[ TOP ]
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Statistical results of PGR in screening data sets for detecting immune reponses.
|
Summary | |
---|---|
Symbol | PGR |
Name | progesterone receptor |
Aliases | NR3C3; nuclear receptor subfamily 3 group C member 3 |
Chromosomal Location | 11q22-q23 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders |
Points in the above scatter plot represent the expression difference of PGR in various data sets.
|
Points in the above scatter plot represent the mutation difference of PGR in various data sets.
|
Summary | |
---|---|
Symbol | PGR |
Name | progesterone receptor |
Aliases | NR3C3; nuclear receptor subfamily 3 group C member 3 |
Chromosomal Location | 11q22-q23 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of PGR. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene. |
Summary | |
---|---|
Symbol | PGR |
Name | progesterone receptor |
Aliases | NR3C3; nuclear receptor subfamily 3 group C member 3 |
Chromosomal Location | 11q22-q23 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of PGR. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by PGR. > Immunoinhibitor > Immunostimulator > MHC molecule |
Summary | |
---|---|
Symbol | PGR |
Name | progesterone receptor |
Aliases | NR3C3; nuclear receptor subfamily 3 group C member 3 |
Chromosomal Location | 11q22-q23 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of PGR. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor |
Summary | |
---|---|
Symbol | PGR |
Name | progesterone receptor |
Aliases | NR3C3; nuclear receptor subfamily 3 group C member 3 |
Chromosomal Location | 11q22-q23 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Distribution of PGR expression across immune and molecular subtypes. > Immune subtype > Molecular subtype |
Summary | |
---|---|
Symbol | PGR |
Name | progesterone receptor |
Aliases | NR3C3; nuclear receptor subfamily 3 group C member 3 |
Chromosomal Location | 11q22-q23 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Associations between PGR and clinical features. > Overall survival analysis > Cancer stage > Tumor grade |
Summary | |
---|---|
Symbol | PGR |
Name | progesterone receptor |
Aliases | NR3C3; nuclear receptor subfamily 3 group C member 3 |
Chromosomal Location | 11q22-q23 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Drugs targeting PGR collected from DrugBank database. |
Details on drugs targeting PGR.
|